Shandong Bailong Chuangyuan Bio-Tech Past Earnings Performance
Past criteria checks 4/6
Shandong Bailong Chuangyuan Bio-Tech has been growing earnings at an average annual rate of 23.1%, while the Food industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 17.9% per year. Shandong Bailong Chuangyuan Bio-Tech's return on equity is 14.5%, and it has net margins of 22.6%.
Key information
23.1%
Earnings growth rate
15.5%
EPS growth rate
| Food Industry Growth | 7.2% |
| Revenue growth rate | 17.9% |
| Return on equity | 14.5% |
| Net Margin | 22.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals
Nov 06
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price
Oct 14Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)
Sep 29Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors
Aug 23Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes
Jun 26Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be
May 06Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance
May 03If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity
Mar 27Revenue & Expenses Breakdown
How Shandong Bailong Chuangyuan Bio-Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,035 | 234 | 60 | 33 |
| 30 Jun 24 | 987 | 221 | 58 | 37 |
| 31 Mar 24 | 926 | 202 | 55 | 33 |
| 31 Dec 23 | 868 | 193 | 50 | 33 |
| 30 Sep 23 | 825 | 174 | 52 | 31 |
| 30 Jun 23 | 742 | 163 | 51 | 27 |
| 31 Mar 23 | 719 | 154 | 33 | 30 |
| 31 Dec 22 | 722 | 151 | 50 | 27 |
| 30 Sep 22 | 732 | 147 | 46 | 31 |
| 30 Jun 22 | 739 | 131 | 45 | 32 |
| 31 Mar 22 | 717 | 128 | 53 | 27 |
| 31 Dec 21 | 653 | 104 | 43 | 23 |
| 30 Sep 21 | 605 | 99 | 43 | 14 |
| 30 Jun 21 | 566 | 97 | 39 | 11 |
| 31 Mar 21 | 540 | 98 | 42 | 13 |
| 31 Dec 20 | 500 | 96 | 34 | 15 |
| 30 Sep 20 | 479 | 93 | 35 | 18 |
| 30 Jun 20 | 464 | 92 | 40 | 18 |
| 31 Mar 20 | 416 | 77 | 44 | 16 |
| 31 Dec 19 | 421 | 83 | 46 | 15 |
| 31 Dec 18 | 356 | 65 | 33 | 11 |
| 31 Dec 17 | 311 | 64 | 25 | 10 |
| 31 Dec 16 | 336 | 65 | 24 | 11 |
Quality Earnings: 605016 has a high level of non-cash earnings.
Growing Profit Margin: 605016's current net profit margins (22.6%) are higher than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605016's earnings have grown significantly by 23.1% per year over the past 5 years.
Accelerating Growth: 605016's earnings growth over the past year (34.5%) exceeds its 5-year average (23.1% per year).
Earnings vs Industry: 605016 earnings growth over the past year (34.5%) exceeded the Food industry -5.8%.
Return on Equity
High ROE: 605016's Return on Equity (14.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xia Sheng | Citic Securities Co., Ltd. |
| Lin Yang | Guosen Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |